Tell your doctor if you are not able to eat or drink as you normally do
In addition, Zhang et al
The study looked at those who quit within less than three months, and those who discontinued between the three-month mark and one year
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Customer Reviews Quick dispatch, all good
Additionally, GLP-1 microdosing may require more frequent check-ins with a patients healthcare provider to ensure the GLP-1 microdose is working as intended and to ensure there are no unanticipated side effects from GLP-1 microdosing